COMMUNIQUÉS West-GlobeNewswire

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

22/04/2024 - 13:30

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by [...]

Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials

22/04/2024 - 13:05

ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today what it considers to be a major milestone. The Company has completed [...]

BioCryst to Report First Quarter 2024 Financial Results on May 6

22/04/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024 [...]

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

22/04/2024 - 13:00

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli [...]

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

22/04/2024 - 12:45

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company [...]

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

22/04/2024 - 12:41

Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse 1 Approval is based on results from the PHASE 3 CARTITUDE- [...]

RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call

22/04/2024 - 12:00

LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

22/04/2024 - 11:00

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting enables Evexta Bio to move forward in clinical development of rupitasertib in [...]

Nexstim Receives NBS 6 System Order from Clinic in Florida, US

22/04/2024 - 10:00

Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new [...]

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

22/04/2024 - 10:00

EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute [...]

Transactions in Connection with Share Buy-back Program Genmab

22/04/2024 - 09:30

Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

22/04/2024 - 08:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

22/04/2024 - 08:00

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli [...]

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

22/04/2024 - 07:30

Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024 Nicox Group cash of €9.1 million on [...]

Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023

22/04/2024 - 07:30

Communiqué de presse Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023 Chiffre d’affaires du Groupe de €4,4 millions (net 1 de €3,9 millions) pour le premier trimestre 2024 [...]

Samsung Bioepis Gains European Commission Approval For PYZCHIVA™, a Biosimilar to Stelara (Ustekinumab)

22/04/2024 - 07:00

PYZCHIVA becomes Samsung Bioepis’ fourth EC-approved immunology biosimilar Sandoz to commercialize PYZCHIVA in Europe INCHEON, Korea, April 22, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that the [...]

Mithra secures court protection measures to advance monetization process

22/04/2024 - 07:00

Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization. Approval of Judicial [...]

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22/04/2024 - 07:00

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further [...]

Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares

22/04/2024 - 07:00

Ipsen conclut un accord d'option pour les droits mondiaux exclusifs des candidats retenus dans le cadre de cette collaboration Une fois le candidat au développement validé, Ipsen sera responsable de la poursuite de son [...]